Gilead And Roche Resolve Tamiflu Licensing Dispute
This article was originally published in The Pink Sheet Daily
Executive Summary
Increased antiviral demand in the face of seasonal flu and the threat of pandemic avian flu leads the firms to settle arbitration over a manufacturing and commercialization agreement.